Clinical trials
Advanced Solid Cancer clinical trials
Below are recruiting advanced solid cancer clinical trials, each written for real people, not researchers. We’re tracking 1,302 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06726148RecruitingPhase 1/Phase 2
Study of ECI830 for advanced breast cancer and solid tumors
This trial is testing a new drug called ECI830, either alone or with another drug, for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. It may be an option if you have HR+/HER2- breast cancer, small cell lung cancer, or a tumor with a specific gene change (CCNE1 amplification).
Los Angeles, CaliforniaAges 18–100 - NCT06657144RecruitingPhase 1
Study of CHS-114 and toripalimab for advanced solid tumors
This study tests a new drug combo (CHS-114 + toripalimab) for people with advanced solid tumors like stomach, esophageal, or colorectal cancer that have already been treated. It aims to see if adding these drugs can help control the cancer better.
Tucson, ArizonaAges 18 years+ - NCT06659341RecruitingPhase 1
Study of BAY3498264 with Sotorasib for KRAS G12C Cancers
This trial tests a new drug (BAY3498264) combined with sotorasib, a targeted therapy, for people with advanced cancers that have a specific genetic change called KRAS G12C. It's for those who have already tried other treatments and need new options.
Albury, New South WalesAges 18 years+ - NCT05394103RecruitingPhase 1/Phase 2
Testing a targeted pill for hard-to-treat solid tumors
This trial tests a new medicine (Q901) that targets a specific cell-control pathway to treat advanced cancers that have stopped responding to standard care. It’s mainly for people with certain solid tumor cancers, aiming to see whether the drug can shrink tumors or control disease.
Phoenix, ArizonaAges 18 years+ - NCT06656390RecruitingPhase 1/Phase 2
Testing ALK201 for advanced solid tumors
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
Denver, ColoradoAges 18–75 - NCT06508307RecruitingPhase 1
A study of an injected virus for advanced solid tumors
This trial tests a new treatment where a virus (GC001) is injected directly into a tumor. The virus is designed to attack cancer cells and may help people with advanced solid tumors that haven't responded to other treatments.
Zhengzhou, HenanAges 18–75 - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06609187RecruitingPhase 1
Study of GNC-077 for advanced breast cancer and other solid tumors
This trial tests a new drug called GNC-077 for people with advanced breast cancer or other solid tumors that have spread. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06607939RecruitingPhase 1
Study of ORB-021 for advanced solid tumors
This trial tests a new drug called ORB-021 for people with advanced solid tumors that have come back or not responded to other treatments. The goal is to see if ORB-021 is safe and how it affects the body.
Scottsdale, ArizonaAges 18 years+ - NCT06561685RecruitingPhase 1
Study of LY4050784 for Advanced Solid Tumors with SMARCA4 Changes
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
Santa Monica, CaliforniaAges 18 years+ - NCT06092580RecruitingPhase 1
Study of AWT020 for advanced solid tumors and lymphoma
This trial tests a new drug, AWT020, for people with advanced cancer (solid tumors or lymphoma) that hasn't responded to other treatments. The goal is to see if it is safe and how well it works.
South Brisbane, QueenslandAges 18 years+ - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
Goodyear, ArizonaAges 18 years+ - NCT06547840RecruitingPhase 1
Study of MOv18 IgE for ovarian, endometrial, and breast cancers with a specific marker
This trial tests a new antibody treatment called MOv18 IgE for patients with advanced ovarian, endometrial, or triple-negative breast cancers that have a protein called folate receptor alpha (FRα) on their tumor cells. The goal is to see if the treatment is safe and effective.
BristolAges 18 years+ - NCT06533332RecruitingPhase 1
Testing ERX-315 for advanced solid tumors
This trial tests a new drug called ERX-315 for people with advanced solid tumors (like breast, ovarian, pancreatic, endometrial, or liver cancer) that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Ryde, New South WalesAges 18 years+ - NCT06500052RecruitingPhase 1
Study of BL-M17D1 for HER2-positive or low-expression digestive tract and other solid tumors
This trial tests a new drug called BL-M17D1 for people with advanced or metastatic HER2-positive or low-expression gastrointestinal cancer and other solid tumors. The goal is to see if it is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06493864RecruitingPhase 1
BL-B16D1 for advanced breast cancer and solid tumors
This trial tests a new drug called BL-B16D1 for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06424665RecruitingPhase 1
Study of FZ-AD005 for advanced solid tumors
This trial tests a new drug called FZ-AD005 for people with advanced solid tumors, especially small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). It may help if standard treatments are no longer working.
Changsha, HunanAges 18–75 - NCT06416007RecruitingPhase 2
Lattice radiation for large tumor palliation
This study tests a new way to deliver radiation called lattice therapy for people with large solid tumors that are causing symptoms. It aims to give a stronger radiation dose to help shrink the tumor and relieve discomfort.
Cincinnati, OhioAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT06380816RecruitingPhase 1/Phase 2
Study of UCB4594 for advanced cancers with HLA-G marker
This trial tests an experimental drug called UCB4594 for people with certain advanced cancers that have not responded to standard treatments. The goal is to see if the drug is safe and effective against tumors that have a specific marker called HLA-G.
LondonAges 18 years+ - NCT06362369RecruitingPhase 1/Phase 2
Oral 7HP349 with immunotherapy for advanced solid tumors
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Aurora, ColoradoAges 18 years+ - NCT06375187RecruitingPhase 1
GC203 TIL for advanced solid tumors
This trial tests an experimental TIL therapy (GC203) for people with advanced solid tumors who have no more standard options. Doctors will take a piece of your tumor, make it into a personalized cell treatment, and give it back to try to fight the cancer.
ShanghaiAges 18–75 - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Tucson, ArizonaAges 18 years+
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid cancer?
- Yes. Clin2 currently lists 1,302 recruiting advanced solid cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.